Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome

ClinicalTrials.gov ID: NCT02844933

Public ClinicalTrials.gov record NCT02844933. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to assess the efficacy of cannabidiol oral solution on hyperphagia-related behavior in patients with Prader-Willi Syndrome (PWS). The secondary objectives of this study are to assess the efficacy, safety and tolerability, impact on quality of life, and impact on physical activity of cannabidiol oral solution in patients with PWS.

Study identification

NCT ID
NCT02844933
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Enrollment
7 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
8 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 9, 2018 (Actual)
Primary completion
Jul 17, 2019 (Actual)
Completion
Jul 31, 2019 (Actual)
Last update posted
Aug 1, 2023

2018 – 2019

United States locations

U.S. sites
7
U.S. states
7
U.S. cities
7
Facility City State ZIP Site status
University of Arizona Tucson Arizona 85724 —
Rady Children's, UC San Diego San Diego California 92123 —
University of Iowa Iowa City Iowa 52242 —
The University of Kansas , Medical Center Kansas City Kansas 66160 —
Johns Hopkins University Baltimore Maryland 21287 —
The University of Oklahoma Health Sciences Center Tulsa Oklahoma 74135 —
Institute for Research and Innovation | MultiCare Health System Tacoma Washington 98405 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02844933, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 1, 2023 · Synced Oct 28, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02844933 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →